edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
Company profile
Ticker
EW
Exchange
Website
CEO
Michael Mussallem
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign • RTI Surgical ...
Former names
CVG CONTROLLED INC
SEC CIK
Corporate docs
Subsidiaries
Edwards Lifesciences LLC • Edwards Lifesciences Services GmbH • Edwards Lifesciences (U.S.) Inc. • Edwards Lifesciences (Japan) Limited ...
IRS number
364316614
EW stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
12 Feb 24
8-K
Edwards Lifesciences Reports Fourth Quarter Results
6 Feb 24
8-K
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
7 Dec 23
10-Q
2023 Q3
Quarterly report
27 Oct 23
8-K
Edwards Lifesciences Reports Third Quarter Results
25 Oct 23
10-Q
2023 Q2
Quarterly report
28 Jul 23
8-K
Edwards Lifesciences Reports Second Quarter Results
26 Jul 23
SD
Conflict minerals disclosure
1 Jun 23
8-K
Departure of Directors or Certain Officers
15 May 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
Transcripts
EW
Earnings call transcript
2023 Q4
6 Feb 24
EW
Earnings call transcript
2023 Q3
25 Oct 23
EW
Earnings call transcript
2023 Q2
26 Jul 23
EW
Earnings call transcript
2023 Q1
26 Apr 23
EW
Earnings call transcript
2022 Q4
31 Jan 23
EW
Earnings call transcript
2022 Q3
28 Oct 22
EW
Earnings call transcript
2022 Q2
29 Jul 22
EW
Earnings call transcript
2022 Q1
27 Apr 22
EW
Earnings call transcript
2021 Q4
27 Jan 22
EW
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
4
DONALD E BOBO JR
13 Mar 24
4
Jean-Luc M Lemercier
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Daniel J. Lippis
7 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
MICHAEL A MUSSALLEM
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Scott B. Ullem
29 Feb 24
4
KIERAN GALLAHUE
26 Feb 24
4
ROBERT W.A. SELLERS
23 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
55.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 986 |
Opened positions | 133 |
Closed positions | 318 |
Increased positions | 287 |
Reduced positions | 401 |
13F shares | Current |
---|---|
Total value | 23.81 tn |
Total shares | 334.29 mm |
Total puts | 471.20 k |
Total calls | 803.33 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 52.36 mm | $3.99 tn |
STT State Street | 26.96 mm | $2.06 tn |
Brown Advisory | 18.18 mm | $1.39 tn |
BK Bank Of New York Mellon | 17.33 mm | $1.32 tn |
Wellington Management | 16.83 mm | $1.28 tn |
Capital International Investors | 9.04 mm | $689.55 bn |
JPM JPMorgan Chase & Co. | 7.78 mm | $593.46 bn |
FMR | 7.50 mm | $572.03 bn |
Fisher Asset Management | 7.13 mm | $543.53 bn |
Amundi | 6.23 mm | $472.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Bobo Donald E JR | Common Stock | Sell | Dispose S | No | Yes | 91.0135 | 14,500 | 1.32 mm | 39,502.693 |
13 Mar 24 | Bobo Donald E JR | Common Stock | Option exercise | Acquire M | No | Yes | 36.75 | 14,500 | 532.88 k | 54,002.693 |
13 Mar 24 | Bobo Donald E JR | Employee Stock Option (Right to Acquire) Common Stock | Option exercise | Dispose M | No | No | 36.75 | 14,500 | 532.88 k | 12,500 |
11 Mar 24 | Lemercier Jean-Luc M | Common Stock | Sell | Dispose S | No | Yes | 91.677 | 14,400 | 1.32 mm | 173,583.779 |
11 Mar 24 | Lemercier Jean-Luc M | Common Stock | Option exercise | Acquire M | No | Yes | 36.75 | 14,400 | 529.20 k | 187,983.779 |
11 Mar 24 | Lemercier Jean-Luc M | Employee Stock Option (Right to Acquire) Common Stock | Option exercise | Dispose M | No | Yes | 36.75 | 14,400 | 529.20 k | 28,800 |
7 Mar 24 | Daniel J. Lippis | Common Stock | Sell | Dispose S | No | Yes | 90.98 | 1,715 | 156.03 k | 17,213.211 |
7 Mar 24 | Daniel J. Lippis | Common Stock | Option exercise | Acquire M | No | Yes | 36.75 | 1,715 | 63.03 k | 18,928.211 |
7 Mar 24 | Daniel J. Lippis | Employee Stock Option (Right to Acquire) Common Stock | Option exercise | Dispose M | No | No | 36.75 | 1,715 | 63.03 k | 1,714 |
4 Mar 24 | Mussallem Michael A | Common Stock | Sell | Dispose S | No | Yes | 87.05 | 16,040 | 1.40 mm | 4,485.82 |
News
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
14 Mar 24
What 9 Analyst Ratings Have To Say About Edwards Lifesciences
7 Mar 24
B of A Securities Upgrades Edwards Lifesciences to Buy
7 Mar 24
Looking Into Edwards Lifesciences's Recent Short Interest
27 Feb 24
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
22 Feb 24
Press releases
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
11 Mar 24
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
23 Feb 24
Edwards Lifesciences Reports Fourth Quarter Results
6 Feb 24
Edwards' EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
2 Feb 24
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
30 Jan 24